Skip to main content
. 2018 Mar 6;20(4):351–363. doi: 10.1016/j.neo.2018.01.011

Figure 3.

Figure 3

(A) Immunostaining of p-STAT3 expression in mouse ventral prostate. Representative images showing the upregulation of p-STAT3 (Tyr 705) in mice with combined loss of p53 and Eaf2 (Eaf2−/−p53−/−) prostate and tumor compared with wild-type (Eaf2+/+p53+/+) and Eaf2+/+p53−/− or Eaf2−/−p53+/+ mice prostate. Images are representative of three mice. (B) Quantitative analysis of p-STAT3–positive epithelial cells of the prostate from different genotype mice. For each genotype, three mice were used. (***P < .001, ****P < .0001) (C) Immunostaining of Bcl-XL in mouse ventral prostate. Representative images showing the upregulation of Bcl-XL in mice with combined loss of p53 and Eaf2 (Eaf2−/−p53−/−) prostate and tumor compared with wild-type (Eaf2+/+p53+/+) and Eaf2+/+p53−/− or Eaf2−/−p53+/+ mice prostate. Images are representative of three mice. (D) Quantitative analysis of Bcl-xL-positive epithelial cells of the prostate from different genotype mice. For each genotype, three mice were used (**P < .01) Magnification is 20×.